IRCT20200105046010N8尚未招募未知
In- Vivo Bioequivalence study of Ligagliptin tablets 5mg (ABIDI Pharmaceuticals, Iran) with brand drug (TRAJENTA® 5mg Boehringer Ingelheim, Germany) in Iranian healthy volunteers.
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •General health(liver, heart, kidney)
- •Body mass index(18-28)
- •Informed consent
- •Age(18-60)
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
尚未招募
不适用
inagliptin / Metformin tablet 2.5/1000mg ABIDI (Liroprim 2.5/1000mg) , In- Vivo Bioequivalence in Iranian healthy volunteers.In this study the bioquivalence of test and brand of LIROPRIM will evaluated..IRCT20200105046010N5Tabriz University of Medical Sciences24
尚未招募
Unknown
Bioequivalence Study of Linagliptin/Metformin 2.5/1000 mg FC. Tablets of The Test Drug (Kharazmi Pharma, Iran)IRCT20200105046010N101Kharazmi Pharmacy24
尚未招募
Unknown
Comparative in vivo evaluation of 2 ?Linagliptin 5 mg Tablet formulations.Diabetes mellitus.Diabetes mellitus due to underlying conditionIRCT20180620040164N65Dorsa Pharmaceutical Co.24
已完成
不适用
Comparative in vivo evaluation of 2 ?Linagliptin 5 mg Tablet formulations.Diabetes mellitus.Diabetes mellitus due to underlying conditionIRCT20180620040164N38Actover Pharmaceutical Co.24
招募中
Unknown
Bioequivalence study of Linagliptin 5mg tabletIRCT20200105046010N88Tabriz University of Medical Sciences24